TriSalus Life Sciences Inc (TLSI)

NASD · Healthcare · Medical Devices · USA

TriSalus Life Sciences Inc is a micro cap company (market value under $300 million) in the Medical Devices industry.

TriSalus Life Sciences is an oncology-focused medical technology company developing innovative drug delivery technologies for solid tumors. The company's TriNav Infusion System, an FDA-cleared device using Pressure-Enabled Drug Delivery technology, is used in interventional radiology procedures for treating liver cancer and metastases. TriSalus also develops delivery devices and investigates nelitolimod, an immunotherapeutic agent, to enhance treatment outcomes.

From its FY2025 annual report (Form 10-K)

Intrinsic value, DCF valuation, financial health and value investing analysis for the TriSalus Life Sciences Inc stock.

Our verdict on TLSI

Overvalued: intrinsic value $0.50 per share, market price $2.30, margin of safety -359.5% (as of 2026-11-17).

A 0.9x revenue multiple, discounted for its losses, values the shares at $0.50; the price of $2.30 is 360% above that value.

ETFs with the most weight in TLSI

10 more funds hold it; the full list is part of the paid plan.

More on TLSI

Browse

Peers in Medical Devices

All 140 Medical Devices stocks

Cheaper than TLSI in Medical Devices

50 more in this industry show a wider margin of safety.

Is TLSI undervalued or overvalued?

TLSI is overvalued (as of the 2026-11-17 close). A 0.9x revenue multiple, discounted for its losses, values the shares at $0.50; the price of $2.30 is 360% above that value.

What is the intrinsic value of TLSI?

$0.50 per share (as of the 2026-11-17 close), against a market price of $2.30. That is a margin of safety of -359.5%. The value comes from the one valuation method that applies to this company, recomputed every night after the US close.